Effectiveness and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV (PWH) in routine clinical practice in Türkiye: 12-month outcomes from the KLIMIK HIV-TR cohort
Makaleler > Tam Makale · 2026
Yazarlar: Halis Akalın, Asuman İnan, Bülent Kaya, Deniz Gökengin, Dilara İnan, Levent Görenek, Hülya Özkan Özdemir, Adalet Altunsoy, Mehtap Aydin, Funda Şimşek, Atahan Çağatay, Selda Sayin Kutlu, Ali Asan, Sabri Atalay, Serhat Birengel, Volkan Korten, Güniz Kayahan, Ahmet Yılmaz, Arzu Nazlı, Yeşim Yıldız, Gönül Çiçek Şentürk, Yeşim Taşova, Selçuk Kaya, Onur Kaya, Sıla Akhan, Tuna Demirdal, Çiğdem Ataman Hatipoğlu, Mustafa Kemal Çelen, İlkay Karaoğlan, Yeşim Çağlar, Aysel Kocagül Çelikbaş, Barçın Öztürk, Arzu Doğru, Petek Konya, Serpil Erol, Nurgül Ceran, Elif Tigen, Buket Ertürk Şengel, Dilek Yağcı Çağlayık, Pınar Öngürü, Gülşen Mermut, Ayşe Merve Parmaksızoğlu Aydın, Burak Sarıkaya, Bircan Kayaaslan, Lütfiye Nilsun Altınal, Ayşe Serra Özel, Uğur Önal, Taner Yıldırmak, Arzu Kantürk, Zarife Abdulleyeva, Firuze Soyak, Gürsel Ersan, Güle Çınar, İrem Akdemir Kalkan, Ayşe Seza İnal, Işıl Deniz Alıravcı, Gül Ruhsar Yılmaz, Emel Azak, Figen Kaptan, Şerife Altun Demircan, Günay Tuncer Ertem, Esra Kaya Kılıç, Ayşe Özlem Mete, Özlem Akdoğan
AIDS Research and Therapy, Uluslararası, Wos, 2026
DOI: 10.1186/s12981-026-00919-9
Özet
BACKGROUND: Phase 3 trials have established the long-term efficacy and safety of BIC/FTC/TAF for both treatment-naïve and treatment-experienced people with HIV (PWH). Real-world evidence in patients with very high baseline viral load remains limited. METHODS: This was a non-interventional, observational, retrospective analysis across 33 tertiary centers participating in the KLIMIK HIV-TR cohort. Adults (≥ 18 years) who initiated single-tablet BIC/FTC/TAF on or before August 31, 2022 were included. The primary endpoint was virological suppression at week-48, defined as HIV-1 RNA < 200 copies/mL. Suppression was further stratified by baseline viral load (< 100,000; > 100,000; > 1,000,000 copies/mL). RESULTS: . Virological suppression (HIV-1 RNA < 200 copies/mL) in treatment-naïve patients was 95.6% and 98.3% at weeks 24 and 48 respectively. When a threshold of < 50 copies/mL was applied, virological suppression rates at weeks 24 and 48 were 81.9% and 93%, respectively. At week 24, virological suppression (HIV-1 RNA < 50 copies/mL) was lower in those with baseline HIV-1 RNA > 100,000 versus < 100,000 copies/mL (80.4% vs. 93.8%; p < 0.001), and lower in those with baseline HIV-1 RNA > 1,000,000 versus < 1,000,000 copies/mL (67.1% vs. 86.9%; p < 0.001). The median CD4/CD8 ratio in treatment-naïve patients increased from 0.44 at baseline to 1.06 at week 48 (p < 0.001). In treatment-experienced patients, week 48 virological suppression was 92.2% (HIV-1 RNA < 50 copies/mL) and 96.5% (HIV-1 RNA < 200 copies/mL). No serious adverse events leading to discontinuation were observed. CONCLUSIONS: High virological suppression rates were observed among both treatment-naïve patients with very high baseline viral loads and treatment-experienced patients, supporting the effectiveness and safety profile of BIC/FTC/TAF in routine clinical practice.